- Home
- SRZN vs LTRN Comparison
SRZN vs LTRN Comparison
Compare SRZN & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- LTRN
- Stock Information
- Founded
- SRZN 2015
- LTRN 2013
- Country
- SRZN United States
- LTRN United States
- Employees
- SRZN N/A
- LTRN N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- LTRN Health Care
- Exchange
- SRZN Nasdaq
- LTRN Nasdaq
- Market Cap
- SRZN 38.1M
- LTRN 36.2M
- IPO Year
- SRZN N/A
- LTRN 2020
- Fundamental
- Price
- SRZN $9.10
- LTRN $3.51
- Analyst Decision
- SRZN
- LTRN Hold
- Analyst Count
- SRZN 0
- LTRN 1
- Target Price
- SRZN N/A
- LTRN N/A
- AVG Volume (30 Days)
- SRZN 30.0K
- LTRN 40.5K
- Earning Date
- SRZN 11-06-2024
- LTRN 11-07-2024
- Dividend Yield
- SRZN N/A
- LTRN N/A
- EPS Growth
- SRZN N/A
- LTRN N/A
- EPS
- SRZN N/A
- LTRN N/A
- Revenue
- SRZN $10,000,000.00
- LTRN N/A
- Revenue This Year
- SRZN N/A
- LTRN N/A
- Revenue Next Year
- SRZN N/A
- LTRN N/A
- P/E Ratio
- SRZN N/A
- LTRN N/A
- Revenue Growth
- SRZN N/A
- LTRN N/A
- 52 Week Low
- SRZN $5.55
- LTRN $3.04
- 52 Week High
- SRZN $16.19
- LTRN $11.99
- Technical
- Relative Strength Index (RSI)
- SRZN 40.89
- LTRN 51.26
- Support Level
- SRZN $8.90
- LTRN $3.04
- Resistance Level
- SRZN $14.18
- LTRN $3.87
- Average True Range (ATR)
- SRZN 1.28
- LTRN 0.23
- MACD
- SRZN -0.26
- LTRN 0.04
- Stochastic Oscillator
- SRZN 3.87
- LTRN 60.84
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.